Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life.
Atopic dermatitis
eczema
pruritus
quality of life
Journal
The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
pubmed:
29
6
2022
medline:
16
8
2022
entrez:
28
6
2022
Statut:
ppublish
Résumé
Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials. These analyses included data for Investigator's Global Assessment responder (clear [0] or almost clear [1] with ≥2-grade improvement) and nonresponder patients with moderate-to-severe atopic dermatitis who received abrocitinib (200 mg or 100 mg) or placebo in three abrocitinib monotherapy trials (phase 2 b, NCT02780167; two phase 3, NCT03349060/JADE MONO-1 and NCT03575871/JADE MONO-2). Outcomes measuring skin clearance, itch, and quality of life were evaluated. Both nonresponders ( Patients with moderate-to-severe atopic dermatitis treated with abrocitinib who did not achieve an Investigator's Global Assessment 0/1 response at week 12 still experienced rapid, clinically meaningful improvements across several other validated measures of efficacy and quality of life. NCT02780167, NCT03349060, NCT03575871.
Sections du résumé
BACKGROUND
UNASSIGNED
Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials.
METHODS
UNASSIGNED
These analyses included data for Investigator's Global Assessment responder (clear [0] or almost clear [1] with ≥2-grade improvement) and nonresponder patients with moderate-to-severe atopic dermatitis who received abrocitinib (200 mg or 100 mg) or placebo in three abrocitinib monotherapy trials (phase 2 b, NCT02780167; two phase 3, NCT03349060/JADE MONO-1 and NCT03575871/JADE MONO-2). Outcomes measuring skin clearance, itch, and quality of life were evaluated.
RESULTS
UNASSIGNED
Both nonresponders (
CONCLUSION
UNASSIGNED
Patients with moderate-to-severe atopic dermatitis treated with abrocitinib who did not achieve an Investigator's Global Assessment 0/1 response at week 12 still experienced rapid, clinically meaningful improvements across several other validated measures of efficacy and quality of life.
CLINICALTRIALS.GOV
UNASSIGNED
NCT02780167, NCT03349060, NCT03575871.
Identifiants
pubmed: 35763326
doi: 10.1080/09546634.2022.2059053
doi:
Substances chimiques
Pyrimidines
0
Sulfonamides
0
abrocitinib
73SM5SF3OR
Banques de données
ClinicalTrials.gov
['NCT03575871', 'NCT03349060', 'NCT02780167']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM